A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series

Lewis, 1998, 1 Guengerich, 2002, Biochemistry, 41, 11025, 10.1021/bi020341k Essioux, 2002, 57 Ashwell, 2004, Bioorg. Med. Chem. Lett., 14, 2025, 10.1016/j.bmcl.2004.02.078 Biller, S. A.; Custer, L.; Dickinson, K. E.; Durham, S. K.; Gavai, A.; Hamann, L. G.; Josephs, J. L.; Moulin, F.; Pearl, G. M.; Flint, I. P.; Sanders, M.; Tymiak, A. A.; Vaz, R. In Pharmaceutical Profiling in Drug Discovery for Lead Selection; Borchardt, R. T., Kerns, E. H., Lipinski, C. A., Thakker, D. R., Wang, B., Eds.; AAPS Press: Arlington, VA, 2004; pp 413–429. Strobl, 1993, J. Med. Chem., 36, 1136, 10.1021/jm00061a004 de Groot, 1999, J. Med. Chem., 42, 4062, 10.1021/jm991058v De Rienzo, 2000, J. Comp. Aided Mol. Des., 14, 93, 10.1023/A:1008187802746 Klebe, 1994, J. Med. Chem., 37, 4130, 10.1021/jm00050a010 Cramer, 1988, J. Am. Chem. Soc., 110, 5959, 10.1021/ja00226a005 Cramer, 1993, 443 Klebe, 1998, Vol. 3, 87 Williams, 2000, Mol. Cell, 5, 121, 10.1016/S1097-2765(00)80408-6 Smith, 1992, Biochem. Pharmacol., 44, 2089, 10.1016/0006-2952(92)90333-E Guengerich, 2002, Biochemistry, 41, 11025, 10.1021/bi020341k Guengerich, 2003, Biochemistry, 42, 1245, 10.1021/bi027085w Hutzler, 2003, Chem. Res. Toxicol., 16, 450, 10.1021/tx025674x